ArticleNature medicine2005
Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.
Article in Nature medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 429 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
429 citing papers in PubMed, 4 syntheses or guidelines pooled it, 974 citations in OpenAlex.
- Beyond urodynamics: non-invasive approaches to diagnosing detrusor underactivity in men with lower urinary tract symptoms - a systematic review.BMC urology · 2025Pooled it
- Adiponectin protects against myocardial ischemia-reperfusion injury: a systematic review and meta-analysis of preclinical animal studies.Lipids in health and disease · 2024Pooled it
- Associations between three common single nucleotide polymorphisms (rs266729, rs2241766, and rs1501299) of ADIPOQ and cardiovascular disease: a meta-analysis.Lipids in health and disease · 2018Pooled it
- Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.Lipids in health and disease · 2016Pooled it
- Total adiponectin is associated with incident cardiovascular and renal events in treated hypertensive patients: subanalysis of the ATTEMPT-CVD randomized trial.Scientific reports · 2019Trial
- Increased serum adiponectin predicts improved coronary flow and clinical outcomes in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.Journal of clinical laboratory analysis · 2019Trial
- Impact of weight reduction on insulin resistance, adhesive molecules and adipokines dysregulation among obese type 2 diabetic patients.African health sciences · 2018Trial
- Weight-Loss Diets, Adiponectin, and Changes in Cardiometabolic Risk in the 2-Year POUNDS Lost Trial.The Journal of clinical endocrinology and metabolism · 2016Trial
- Inflammatory signalling in diabetic cardiomyopathy: molecular mechanisms and potential therapeutic strategies.Nature reviews. Cardiology · 2026Review
- ALY688 Protects Against Myocardial Ischemia-Reperfusion Injury via Direct Effects and Rab8a-Dependent Extracellular Vesicles.Journal of extracellular vesicles · 2026Article
- Refined Carbohydrate-Rich Diet Promotes Early Myocardial Dysfunction Associated with Adiponectin Reduction, Inflammation, and Impaired CaNutrients · 2026Article
- The Obesity Paradox in Major Adverse Cardiovascular Events After PCI for Acute Coronary Syndrome: A Narrative Review.Journal of cardiovascular development and disease · 2026Review
- Extracellular Vesicles Modulation by an Adiponectin Receptor Agonist Provides Cardioprotection for Myocardial Ischemic Injury.Advanced healthcare materials · 2026Article
- Differential Therapeutic Modulations of Adiponectin: Beneficial, Adverse, and Context-Dependent Effects in Chronic Coronary Syndromes.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026Review
- When Fat Speaks: Decoding the Signals of Epicardial Adipose Tissue after Acute Coronary Syndrome.Journal of atherosclerosis and thrombosis · 2026Article
- Body weight and mortality in Takotsubo syndrome: insights from the International Takotsubo (InterTAK) Registry.Open heart · 2026Observational
- Adipose immune microenvironment: catalyst of age-related adipose tissue dysfunction.Immunity & ageing : I & A · 2025Review
- A glucose kinase-independent HK2 activity prevents TNF-induced cell death by phosphorylating RIPK1.Nature communications · 2025Article
- Predictive Value of Adiponectin for Long-Term MACEs in Non-Diabetic STEMI Patients.Journal of clinical medicine · 2025Article
- The Cardioprotective Effects of Adiponectin in Diabetes.Current diabetes reports · 2025Review
369 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Obesity-related disorders are associated with the development of ischemic heart disease. Adiponectin is a circulating adipose-derived cytokine that is downregulated in obese individuals and after myocardial infarction. Here, we examine the role of adiponectin in myocardial remodeling in response to acute injury. Ischemia-reperfusion in adiponectin-deficient (APN-KO) mice resulted in increased myocardial infarct size, myocardial apoptosis and tumor necrosis factor (TNF)-alpha expression compared with wild-type mice. Administration of adiponectin diminished infarct size, apoptosis and TNF-alpha production in both APN-KO and wild-type mice. In cultured cardiac cells, adiponectin inhibited apoptosis and TNF-alpha production. Dominant negative AMP-activated protein kinase (AMPK) reversed the inhibitory effects of adiponectin on apoptosis but had no effect on the suppressive effect of adiponectin on TNF-alpha production. Adiponectin induced cyclooxygenase (COX)-2-dependent synthesis of prostaglandin E(2) in cardiac cells, and COX-2 inhibition reversed the inhibitory effects of adiponectin on TNF-alpha production and infarct size. These data suggest that adiponectin protects the heart from ischemia-reperfusion injury through both AMPK- and COX-2-dependent mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.